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Abstract
The E6 and E7 proteins of high-risk HPVs are both required for the immortalization of primary human keratinocytes and the maintenance of
the malignant phenotype of HPV-positive cancer cell lines. Our previous studies have shown that E6 protein binds Myc protein and that both E6
and Myc associate with and cooperatively activate the hTERT promoter, thereby increasing cellular telomerase activity. In this study, we evaluated
the role of E7 in the maintenance and activation of telomerase in immortalized and tumorigenic cells. siRNA knockdown of either E6 or E7 (or
both) in HPV-immortalized cells or an HPV-positive cancer cell line reduced hTERT transcription and telomerase activity. Since telomerase was
inhibited by E7 siRNA in cells that independently expressed the E6 and E7 genes, our results reveal an independent role for E7 in the maintenance
of telomerase activity. However, E7 alone was insufficient to increase endogenous hTERT mRNA or telomerase activity, although it significantly
augmented E6-induced hTERT transcription and telomerase activity. To further explore this apparent E7-induced promoter augmentation, we
analyzed an exogenous hTERT core promoter in transduced keratinocytes. E7 alone induced the wt hTERT promoter and augmented E6-induced
hTERT promoter activity. Mutation of the E2F site in the hTERT promoter abrogated the ability of E7 to induce the hTERT promoter or to
enhance the ability of E6 to induce the promoter. Correspondingly, keratinocytes expressing E6 and a mutant E7 (defective for binding pRb pocket
proteins) showed lower telomerase activity than cells expressing wt E6 and wt E7. Thus, HPV E7 plays a role in the maintenance of telomerase
activity in stable cell lines and augments acute, E6-induced hTERT promoter activity.
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The high-risk human papillomaviruses (HPV16, 18) are
critical etiologic agents in human malignancy, most importantly
in cervical cancer (zur Hausen, 2002). These oncogenic viruses
encode the E6 and E7 proteins which are uniformly retained and
expressed in cervical cancers (Androphy et al., 1987; Banks
et al., 1987; Schwarz et al., 1985) and their continued expression
is required for the cells to retain the tumorigenic phenotype.
Inhibiting expression of these genes leads to inhibition of cell
growth (Butz et al., 2003; Fujii et al., 2006; Venturini et al.,
1999; Vormwald-Dogan et al., 1992) and the specific ablation of
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doi:10.1016/j.virol.2008.02.025culture for decades) leads to cell apoptosis or senescence
(DeFilippis et al., 2003; Hall and Alexander, 2003). The E6 and
E7 proteins were first identified as targeting the p53 and pRb
tumor suppressor pathways in host cells (Munger and Howley,
2002), thereby leading to disruption of cell cycle controls. The
simultaneous expression of E6 and E7 appears to be requisite for
cervical cancer and indeed these two genes seem to have evolved
complementary functions (zur Hausen, 2002). E7 stimulates the
cell cycle via its ability to bind and inactivate the cellular pRb
protein (Munger et al., 2001, 1989b), and this stimulatory effect
has the potential to enhance apoptosis in primary cells (Stoppler
et al., 1998). However, this apoptotic pathway is blocked by the
ability of E6 to prevent apoptosis via inhibition of p53 and Bak
(Pan and Griep, 1994, 1995; Steller et al., 1996; Thomas and
Banks, 1998). Reciprocally, the ability of E6 to transform cells
appears to be inhibited by the expression of p16 which inhibits
cyclin D1-cdk4 or cyclin D1/cdk6 complexes. The E7 protein
bypasses this blockade apparently by activating certain cyclins
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immortalization of primary genital keratinocytes by HPV relies
upon the cooperative activity of these two viral genes (Hawley-
Nelson et al., 1989; Munger et al., 1989a).
E6 displays several activities which might be relevant to its
role in cervical neoplasia, including its cooperation with Ras in
the transformation of primary rodent cells (Liu et al., 1994; Pim
et al., 1994; Storey and Banks, 1993), inhibition of apoptosis
(Alfandari et al., 1999; Pan and Griep, 1995; Steller et al., 1996;
Thomas and Banks, 1998), interference with cell differentiation
(Pan and Griep, 1994; Sherman et al., 2002, 1997; Sherman and
Schlegel, 1996; Thomas and Banks, 1998), immortalization of
primary mammary epithelial cells (Band et al., 1991; Liu et al.,
1999), cooperation with E7 in the immortalization of human
genital keratinocytes (Hawley-Nelson et al., 1989;Munger et al.,
1989a), and induction of malignant tumors in transgenic mice
(Griep et al., 1993; Song et al., 2000, 1999). Corresponding to
this multitude of activities, the E6 protein can bind a plethora of
cellular proteins (Hebner and Laimins, 2006; Mantovani and
Banks, 2001; Munger et al., 2004; Munger and Howley, 2002).
Another major function of HPV E6 is its ability to activate the
expression of the catalytic subunit of the telomerase, hTERT
(Gewin and Galloway, 2001; Klingelhutz et al., 1996; Oh et al.,
2001; Veldman et al., 2001), which is critical for cell im-
mortalization, therebymaintaining chromosome telomere length
and continued cell proliferation(Kiyono et al., 1998). Although
this function of E6 is independent of p53 degradation and its
PDZ binding ability, it appears to require E6AP (Gewin et al.,
2004; James et al., 2006; Liu et al., 2005). We and others have
shown that E6 appears to activate hTERT transcription through
Myc binding sites in the hTERT promoter (Gewin andGalloway,
2001; Oh et al., 2001; Veldman et al., 2001). However, E6 does
not induce Myc expression (Galloway et al., 2005; Gewin and
Galloway, 2001; Oh et al., 2001; Veldman et al., 2001) nor
increase Myc binding to the hTERT promoter (Galloway et al.,
2005; Sekaric et al., 2008; Veldman et al., 2003); Myc protein
binds to the promoter in the presence or absence of E6 protein in
keratinocytes (Galloway et al., 2005; Sekaric et al., 2008;
Veldman et al., 2003). Interestingly, E6 associates with Myc in
vivo and in vitro and both bind to the core hTERT promoter
(Veldman et al., 2003). E6 also increases histone acetylation on
the promoter (Galloway et al., 2005, our unpublished data;
James et al., 2006), suggesting that it might alter the local
chromatin structure and enhance promoter activity. The core
hTERT promoter is relatively weak and contains multiple po-
tential binding sites for transcription factors, including E2F, Sp1,
NF-kB, and Ets (Fig. 3A). Three potential intact E2F sites
brought our attention to the possibility that HPV E7 might
participate in the transactivation of hTERT.
The HPV E7 protein is a low-molecular-weight protein of
approximately 100 amino acids. Like E6, E7 also appears to be a
multifunctional oncoprotein; it interacts with the pRb, p107 and
p130 proteins through a conserved LXCXE sequence within the
CR2 sequences (Dyson et al., 1992; Dyson et al., 1989). These
pocket proteins regulate the activities of the E2F family of
transcription factors that control multiple cell cycle transitions as
well as other cellular activities (Cam and Dynlacht, 2003). Theability of E7 to destabilize pocket proteins is critical for cellular
transformation (Gonzalez et al., 2001; Helt and Galloway, 2001;
Jones et al., 1997). In addition to binding and degrading pRb and
its related pocket proteins (p107, p130), E7 has other cellular
targets that are relevant to cellular transformation. HPV E7 can
override the growth-inhibitory activities of cyclin-dependent
kinase inhibitors, including p21CIP1 (Funk et al., 1997; Jones and
Munger, 1997) and p27KIP1 (Zerfass-Thome et al., 1996). Addi-
tional E7-interacting proteins, including transcription factors
p300, CBP, and pCAF (Avvakumov et al., 2003; Bernat et al.,
2003; Huang and McCance, 2002), cell cycle regulators
cyclin A, cyclin E, p21, p27, and metabolic enzymes, have
been isolated by various methods, and many of these candidates
appear to associate with carboxyl-terminal E7 sequences
(Munger et al., 2001). The carboxyl-terminal HPV E7 domain
also contributes to association with chromatin-modifying
enzymes, particularly histone deacetylases (HDACs) and
histone acetyl transferases (HATs) (Brehm et al., 1999). Each
of the above E7-interacting proteins might contribute to trans-
forming activities of high-risk HPV E7 proteins. More recently,
E7 has been shown to interact with a pRb-associated protein,
p600(DeMasi et al., 2005; Huh et al., 2005), and induce genetic
instability, predominantly via its ability to induce abnormal
centrosome numbers and multipolar mitotic spindles (Duensing
and Munger, 2002; Munger et al., 2004, 2001; Piboonniyom
et al., 2003).
In the current study we utilized E6 and E7 siRNAs to dem-
onstrate that E7 contributes to the sustained telomerase activity
in E6/E7-immortalized keratinocytes and tumor cells. In ad-
dition, real-time quantitative TRAP assays showed that E6/E7-
transduced cells had a higher telomerase activity than E6-
transduced cells and that the augmentation by E7 required pRb
binding and an intact E2F site in the hTERT promoter.
Results
Generation and characterization of keratinocyte cell strains
expressing the HPV-16 E6 and E7 oncogenes
Recently, several studies have demonstrated that E2F strongly
regulates the hTERT promoter (Alonso et al., 2005, 2006; Crowe
and Nguyen, 2001; Crowe et al., 2001; Won et al., 2004), at least
in glioblastoma cancer cells and fibroblasts. Since the HPV-16 E7
protein inactivates the pRb tumor suppressor and releases the
repression of E2F target genes, we hypothesized that E7 might
also regulate the hTERT promoter in keratinocytes. To address
this possibility, we constructed retroviruses with pLXSN vector,
pLXSN-16E6, pLXSN-16E7 or pLXSN-16E6/E7 and then
generated keratinocyte strains expressing these constructs
(Stoppler et al., 1997; Veldman et al., 2001). To confirm the
appropriate gene expression (E6, E7) in the cell lines, RT-PCR
was performed with E6- or E7-specific primers (Fig. 1A). As
anticipated, E6 mRNA was expressed in HFKs transduced with
the E6 and E6/E7 retroviruses, while E7 mRNAwas expressed in
the E7 and E6/E7 transduced cells. HFKs transduced with the
pLXSN vector served as the control, and GAPDH was used to
normalize gene expression (Fig. 1B).We also performed reactions
Fig. 1. Generation and characterization of keratinocyte strains expressing the
HPV-16 E6 and E7 genes. (A): Diagram of HPV-16 E6 and E7 mRNA
expression and locations of primers and siRNA targets used in this study. The E6
and E7 open reading frames (ORFs) are shown as open boxes, with the
nucleotide positions of the first nucleotide of the start codons and the last
nucleotide of the stop codons indicated. The dotted lines flanking the open boxes
and the heavy lines represent vector sequences. The heavy lines below the open
boxes represent the E6/E7 bicistronic transcripts with alternative splicing sites
depicted as dotted lines. The numbers above the full length E6/E7 transcript are
the nucleotide positions of the first nucleotide of the start codon of E6 and the
last nucleotide of the stop codon of E7 in the HPV16 genome. The numbers
above the E6⁎IE7 and E6⁎IIE7 transcripts are the positions of either 5′ or 3′
splicing sites. The primers used in this study are depicted below the transcript
lines as arrows and numbers showing the locations of primers in the genome.
The siRNA targets are also depicted as dashes and numbers showing the start
and end nucleotides of the targets. (B): confirmation of E6, E7 mRNA
expression. Primary human foreskin keratinocytes (HFK) were transduced with
pLXSN expressing HPV-16 E6, E7, E6/E7 or empty vector as described. Total
cellular RNA was isolated from the transduced HFK cell strains and RT-PCR
was performed with sets of HPV16 unspliced E6 and E7 specific primers
described in Material and Methods, GAPDH mRNAwas detected as an internal
control. PCR products were analyzed with 2% agarose gel. (C): p53 and pRb
proteins. To verify the expression of the E6 and E7 proteins, we screened the
above stable cell lines by Western blotting for expression of p53 and pRb,
respectively. Western blotting for β-actin also was used as a loading control. As
anticipated, a decreased p53 protein was observed in E6 and E6/E7 expressing
cells, and decreased pRb was only observed in E7-expressing cells.
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came from mRNA, not DNA (data not shown). To further verify
whether the E6 and E7 were functional in the stable cell lines, we
assayed the level of tumor suppressor p53 and pRb in these lines
by Western blotting (Fig. 1C). The data showed decreased p53
levels in E6-transduced cells and reduction of pRb protein in E7-
expressing cells, respectively.
Specificity of E6 and E7 siRNA duplexes
To study the role of E6 and E7 in the regulation of telome-
rase, we used the small interfering RNA (siRNA) technique
depicted in Fig. 1A. In the keratinocyte strain with combined
E6/E7 genes, the E6 siRNA (which targets the unspliced E6
mRNA that produces E6 protein but not the spliced mRNAs that
produce E7) decreased unspliced E6 mRNA levels but not E7
mRNA levels (Fig. 2A). A similar strategy has been used to
knockdown E6 expression without affecting E7 expression
(Butz et al., 2003; Kelley et al., 2005; Tang et al., 2006). In
contrast, the E7 siRNA decreased both E7 mRNA and unspliced
E6 mRNA due to the bicistronic early mRNA in these cells
(Fig. 2A). We also used siRNA to knock down Myc expression
since this cellular protein is the target by which E6 induces
hTERT mRNA. Myc siRNA also serves as a specificity control
for the E6 and E7 siRNAs. Neither scrambled nor Myc siRNAs
affected E6 or E7 expression. Confirming that both the E6 and
E7 siRNAs decreased E6 protein levels, we observed that the
amount of p53 in these transfected cells was markedly elevated
(Fig. 2B). We applied the same siRNAs to the keratinocyte
strain expressing separate E6/E7 genes (Fig. 2C). The E6 and
E7 siRNAs specifically decreased E6 and E7 transcription,
respectively. Corresponding with the specific inhibition of E6
and E7 expression, only the E6 siRNA (but not the E7 or Myc
siRNAs) dramatically restored p53 protein level in these cells
(Fig. 2D). While we did not look at the phenotype of cell gowth
or apoptosis for 48 h treatment with siRNAs, based upon pre-
vious studies (DeFilippis et al., 2003; Nishimura et al., 2006;
Tang et al., 2006), we anticipate that selective inhibition of E6
or E7 would result in apoptosis or senescence during the course
of treatment, respectively.
E6/E7 expression is required for the maintenance of telomerase
activity in HPV-immortalized and tumorigenic cervical cells
E6 and E7 are required for the efficient immortalization of
primary HFKs as well as the maintenance of the malignant
phenotype of HPV-positive cancer cells. Similarly, telomerase
activity is also critical for immortalization and the maintenance
of a malignant phenotype. We therefore speculated that the HPV
oncoproteins played an important role in the continued expres-
sion of telomerase in HPV positive cancers and E6/E7 im-
mortalized cells. To test this hypothesis, we selectively knocked
down expression of E6 (using the E6 siRNA construct, Fig. 1A)
or E6/E7 (using the E7 siRNA construct, Fig. 1A) in HPV
positive cervical cancer cells (SiHa cells) and E6/E7 immorta-
lized HFKs with siRNA duplexes. The level of telomerase
activity in these cells was reduced 50–70% by the E6, E7 and
Fig. 2. siRNA knockdown of E6 and E7 expression in E6/E7 transduced keratinocytes. (A) RT-PCR detection of E6 and E7 mRNA (upper and middle panels) and
GAPDH mRNA (bottom panel) in keratinocytes expressing the combined E6/E7 genes. The PCR signal for E6 mRNAwas reduced in cells treated with siRNA for
either E6 or E7. E7 mRNAwas decreased in cells treated with siRNA for E7 only. Myc and control siRNA duplexes did not affect the expression of either E6 or E7.
The expression of GAPDH mRNAwas unaffected by any of these treatments. (B) Western blot detection of p53 protein (upper panel) and β-actin (bottom panel) in
HFKs treated with siRNAs. Keratinocytes were treated identically with siRNAs for E6, E7, or Myc as described in (A) but were then analyzed for p53 protein
expression byWestern blot. p53 protein was increased in cells treated with either E6 or E7 siRNAs, consistent with their postulated inhibition of E6 protein expression.
Cells treated with Myc or control siRNA showed lower levels of p53, consistent with continued E6 expression. β-actin protein expression was not altered by any
siRNA treatment. (C) RT-PCR detection of E6 and E7 mRNA (upper and middle panels) and GAPDH mRNA (bottom panel) in HFKs that express E6 and E7 from
separate vectors. In contrast to experiments with cells expressing the combined E6/E7 genes (panels A–B), cells expressing the E6 and E7 genes from separate vectors
showed a specific inhibition by respective siRNAs. E6 mRNAwas reduced only when treated with E6 siRNA and E7 mRNAwas decreased only in cells treated with
E7 siRNA.Myc and control siRNA duplexes had no effect on E6 or E7 expression. The expression of GAPDHmRNAwas unaffected by these treatments. (D)Western
blot detection of p53 protein (upper panel) and β-actin (bottom panel) in HFKs expressing the E6 and E7 genes from separate vectors. p53 was increased only in cells
that were treated with E6 siRNA, indicating specific knockdown of E6 in these cells. These results also verify the results in panel C demonstrating that the E7 siRNA is
not inhibiting E6 expression.
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on continued viral oncoprotein expression as well as on Myc
expression (Fig. 3A). Thus, these data indicate that E6 and Myc
are required for maintenance of telomerase activity. Whether E7
protein expression is required cannot be evaluated in these
experiments due to the dual effect of the E7 siRNA on both E6
and E7 mRNA. The potential role of E7 is considered in the
next section. These data are consistent with previous studies of
HeLa cells in which E2-repressed HPV-18 E6/E7 genes were
replaced by the HPV-16 E6 and E7 genes (DeFilippis et al.,
2003; Nishimura et al., 2006), as well as studies of HPV
positive cancer lines (HeLa and SiHa cells) in which E6 or E6/
E7 siRNAs were used (Tang et al., 2006).
The E6, E7 and Myc siRNAs were also able to significantly
inhibit telomerase activity in SiHa cervical cancer cells (Fig. 3B),
suggesting a similar dependence upon the viral oncogenes and
Myc. However, similar to the limitations in Fig. 3A, we cannot
conclude an independent role for E7 in these cells since the E7
siRNA also affects E6 mRNA levels.
Finally, to evaluate the presumed dependence of hTERT
promoter activity on E6/E7 expression in cervical cancer cells,we compared the activity of a transfected hTERT promoter
(expressing luciferase) in HPV-16 positive and HPV-negative
cervical cancer cells. While both E6 and E7 siRNAs decreased
hTERT promoter activity in SiHa cells, neither siRNA affected
hTERT promoter activity in the HPV-negative C33A cell line
(Fig. 3C).
E7 is also required for the maintenance of telomerase and is
independent of E6
To demonstrate that telomerase activity was also dependent
upon E7 protein, we generated keratinocyte cell lines that were
immortalized by the E6 and E7 genes expressed separately by
different vectors. This would allow us to bypass the complex
alternative splicing of the bicistronic E6/E7 genes and regulate E6
and E7 gene expression individually. In these cells, siRNAs to the
E6 and E7 were able to differentially and selectively inhibit the
expression of the corresponding mRNAs (Fig. 2C). This selective
inhibition was verified by the ability of the E6 siRNA, but not the
E7 siRNA, to inhibit E6 protein and thereby increase cellular p53
levels (Fig. 2D). Similar to the results in Fig. 3A, the siRNA for
Fig. 3. E6/E7 contribute to the telomerase activity of E6/E7 immortalized HFKs
and HPV-positive tumor cells. (A) Telomerase activity inhibition by siRNAs in
E6/E7 expressing HFKs. Telomerase activity was measured with a quantitative
assay in cells treated with the above siRNAs. Consistent with their ability to
inhibit E6, the siRNAs for E6 and E7 decreased telomerase activity by
approximately 50%. Myc siRNAwas used as a positive control since it has been
shown to inhibit cellular telomerase activity. (B) Telomerase activity in SiHa
cells after siRNA transfection. Telomerase activity was also reduced in SiHa
cancer cells by approximately 50% after treatment with either the E6 or E7
siRNA duplexes. However, since the SiHa cells express E6/E7 coordinately, we
cannot conclude an independent role for E7 from these experiments. (C) hTERT
promoter activity in tumor cells with siRNA treatment. The wild-type hTERT
promoter reporter vector was transfected into the indicated cells together with
siRNA for either E6, E7, or control. The value of the promoter activity with
control siRNA was set to 100. The hTERT activity was reduced in SiHa cells
after treatment with either E6 or E7 specific siRNA by approximately 70% and
80% respectively. Importantly, in cervical cancer cells which lack HPV-16 E6/
E7 (C33A), the siRNAs showed no significant inhibition of telomerase activity.
Fig. 4. E7 contributes to the telomerase activity of E6/E7 immortalized cells.
(A) Telomerase activity is dependent upon E7. HFKs expressing the separate E6
and E7 genes were transfected with either the E6 and E7 siRNAs and quantified
for telomerase activity as described. Both siRNAs decreased telomerase activity
when transfected into recipient cells. Thus, E7 is required for full telomerase
activity and its effect on the hTERT promoter is independent of E6. As shown
previously in panel C, Myc siRNA also inhibited telomerase activity. (B) hTERT
promoter activity is also dependent upon E7. An hTERT promoter reporter
construct was transfected into the indicated cells together with siRNA for either
E6, E7, or control siRNA. The value of the promoter activity with control siRNA
was set to 100. hTERT promoter activity was reduced dramatically in both types
of HFKs after treatment with either E6 or E7 specific siRNA. However, only the
experiment with HFKs expressing the separate E6 and E7 genes conclusively
demonstrates the specific requirement for E7 in maintaining full telomerase
activity.
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(Fig. 4A). However, the experiments in Fig. 4A now allow us to
conclude that E7 is independently responsible for significant
telomerase activity in E6/E7 immortalized cells. As expected, we
also observed an siRNA-dependent decrease in promoter activity
in the two keratinocyte lines expressing the E6/E7 genes together
or separately (Fig. 4B).Qualitative assays indicate that HPV E6, but not E7, increases
hTERT mRNA and telomerase activity in primary keratinocytes
In support of previous findings, (Kiyono et al., 1998;
Klingelhutz et al., 1996; Stoppler et al., 1997; Veldman et al.,
2001), qualitative assays demonstrated that telomerase activity
was detectable in E6- or E6/E7-expressing cells but not in
vector- or E7-expressing cells (Fig. 5B). Correlating with this
increase in enzymatic activity, hTERT mRNA was expressed
selectively in E6- or E6/E7-expressing cells (Fig. 5A). In con-
trast, there was no increase in hTERC mRNA levels (Fig. 5A),
consistent with the hypothesis that hTERT is a limiting factor
for telomerase activity. GAPDH was used as an internal control
for RT-PCR (Fig. 5A). While these results seem straight-
forward, we noted variations in several independent qualitative
assays, which suggested at times that E7 might enhance hTERT
promoter activity. We therefore utilized quantitative assays to
re-evaluate these findings.
Fig. 5. E7 augments E6-induced hTERT transcription and telomerase activity. (A) hTERT and hTERC mRNA expression in stable keratinocyte cell lines. hTERT
mRNA and hTERC RNAwere detected with sets of the primers described in Materials and Methods. Detectable hTERT mRNAwas observed only in cells expressing
the E6 gene. hTERC RNAwas expressed constitutively in all cell strains. (B) Telomerase activity. A qualitative TRAP assay was performed as described in Materials
andMethods. A typical DNA ladder (6-base pair difference per band) was generated by cellular telomerase in the cell extract of keratinocytes transduced with the E6 or
E6/E7 genes. (C) Quantitative RT-PCR detection of hTERT mRNA. A real time quantitative RT-PCR was performed to quantify hTERT mRNA levels shown in
panel A. These quantitative data demonstrated reproducible, higher hTERTmRNA levels in E6/E7 expressing cells than in E6 expressing cells. (D) Quantitative TRAP
detection of telomerase activity. A quantitative-TRAP assay (Materials and Methods) was also performed to quantify the changes observed in panel B. The E6/E7 cells
showed higher telomerase activity than E6 cells, correlating with the hTERT mRNA levels shown in panel C.
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combination with E6, does augment telomerase activity and
hTERT mRNA expression
Using a quantitative real time TRAP technique described in
Materials and Methods, we assayed cell extracts from keratino-
cytes transduced with pLXSN, E6, E7 and E6/E7. Supporting the
qualitative data in Fig. 5B, our quantitative data demonstrated a
significant activation of telomerase in cells expressing either E6
or E6/E7 (Fig. 5D). However, we consistently noted a higher
telomerase activity in E6/E7 expressing cells (relative activitywas
452±4.36, Fig. 5D) compared to those expressing E6 alone
(relative activity was 263±15.5, Fig. 5D). In addition, we noted a
small but reproducible increase of telomerase activity in E7 cells
(relative telomerase activity of 16.3±2.9) compared to LXSN
control cells (relative activity of 11.6±2.6) (Fig. 5D). To deter-
mine if this E7-dependent increase might reflect enhanced tran-
scription of the hTERT promoter, we measured hTERT mRNA
levels in stable cell lines with quantitative RT-PCR (Fig. 5C). Ourresults demonstrated that hTERT mRNA levels paralleled the
quantitative telomerase findings. Thus, E7 does enhance hTERT
mRNA levels, presumably by increasing the activity of the
hTERT promoter. Direct tests of promoter activation were
pursued.
E7 induces and further augments E6-induced exogenous
hTERT promoter activity
To determine if the E7-augmented expression of hTERT
mRNAwas related to promoter activity, we used an exogenous
hTERT reporter construct (luciferase). We cotransfected empty
vector, E6, E7 or E6/E7 simultaneously with an hTERT core
promoter (pGL3B-hTERT) into primary HFKs and measured
the relative promoter activity. We observed a higher promoter
activity (9–12 fold) with E6/E7 compared to that with E6 alone
(5–8 fold) (Fig. 6B). This is consistent with our quantitative
telomerase activity and hTERT mRNA levels (Figs. 5C, D).
We also observed a 2-fold induction of the core hTERT
Fig. 6. E7 induces the hTERT promoter through an intact E2F site. (A) Diagram of the hTERT core promoter. Binding sites for transcription factors are indicated as
well as the transcription and translation start sites. The sequences and positions of wt and mutated E2F are also depicted. (B) E7 augments E6-induced hTERT
promoter activity and this augmentation requires an intact E2F binding site. The wild-type hTERTcore promoter (pGL3B-hTERT) was mutated at the E2F binding site
using an overlapping PCR protocol described in Materials and Methods. Keratinocytes were transfected with either wt hTERT core promoter (pGL3B-hTERT) or the
E2Fm mutant (pGL3B-hTERT-E2Fm) and either E6, E7 or both. The pRL-CMV R. reniformis reporter plasmid was also transfected into the cells to standardize for
transfection efficiency. Relative fold activation reflects the normalized luciferase activity induced by E6 and E7 compared to the normalized activity of vector control.
The value of pGL3B-hTERT activity with empty vector was set to 1. Error bars show the standard deviation for at least three independent experiments. The mutated
E2F binding site in the core hTERT promoter led to an increased basal activity of the promoter and abrogated E7 induction and augmentation of the promoter. Mutation
of the E2F binding site did not affect E6 induction of the promoter compared to vector.
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induce detectable increases in telomerase and hTERT mRNA
is most likely due to its parallel ability to induce the hTERT
promoter.
E7 augmentation of hTERT promoter activity requires an intact
E2F site in the core hTERT promoter
Since the above experiments indicate that E7 appears to exert
its effect on telomerase activity via the hTERT promoter, we
pursued a mutagenic analysis of the core promoter. Interest-
ingly, three potential E2F binding sites in the hTERT core
promoter have been reported (Alonso et al., 2005, 2006; Croweand Nguyen, 2001; Crowe et al., 2001; Won et al., 2004),
although only one of these (position nt-15 to nt-4) is an optimal
binding site and can regulate the hTERT promoter in fibroblasts
(Fig. 6A). To test whether the proximal E2F site regulated E7
activity in keratinocytes, we mutated the site (CGGCGCGAGT-
TT to CGGAACGATTT) with overlapping PCR and performed
luciferase assays using both wt and mutated hTERT promoters
(E2Fm). Compared to wt hTERT promoter (wt E2F), the E2Fm
promoter exhibited a higher basal activity (3.25±0.48 vs 1±0,
pb0.01, Fig. 6B), suggesting that the E2F site was functioning
as an inhibitory cis-element in primary keratinocytes. While E6
appeared to induce the mutant promoter (15–24 fold vs vector
control with wt promoter) more efficiently than the wt promoter
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actually the same as observed with the wt promoter after the
data was normalized to the vector. Importantly, however, E7 did
not further induce the mutant hTERT promoter compared to
vector control and could not further augment induction of the
mutant promoter by E6. This demonstrates that the release of
hTERT promoter repression by mutation of the E2F site negatesFig. 7. Augmentation of E6-induced hTERT expression and telomerase activity
by E7 requires pRb binding. (A)Mutation of the E2F binding site in E7 abolishes
the enhancement of hTERT transcription. Wild type and E2Fm promoters
(expressing luciferase) were transfected into keratinocytes along with either, E6,
E7 or an E7 mutant (E7 m), which is unable to bind and degrade pRb. In contrast
to wild-type E7, E7m failed to induce the core hTERTpromoter and augment E6-
induced promoter activity. (B) Neither wt E7 nor E7m induce the hTERT
promoter containing an mutated E2F binding site. The mutated hTERT prompter
(E2Fm) was transfected into keratinocytes with expression vectors described in
panel A. The activity of vector control was set to 1. Both the wt and mutant E7
proteins were unable to induce the mutated hTERT promoter or augment E6-
induced promoter activity. (C)Wild-type E7, but not E7m, augments E6-induced
telomerase activity in HFKs. Primary HFKs were doubly transduced with two
types of retroviruses as described inMaterials andMethods. The cell strains were
analyzed using a quantitative telomerase assay. Paralleling the results observed
with transcription of the hTERT promoter (panel A), we observed that the E7 m
protein was unable to enhance E6-induced telomerase activity.the ability of E7 to induce the promoter and suggests that E7/
pRb interactions are critical for this induction.
E7 augmentation of the hTERT promoter activity requires
binding to pRb pocket proteins
To further determine whether the effects of E7 on the hTERT
promoter reflected its ability to bind pRb pocket proteins and
inactivate the ability of E2F to repress the promoter, we made an
E7 mutant (Del 21–24 aa) that was defective for pRb binding.
We speculated that a pRb-binding defective mutant of E7 would
be unable to alter the interaction of pRb with the E2F site and
therefore would be defective for relieving repression of the
hTERT promoter. Our results confirmed this hypothesis. The E7
mutant (E7m) could not induce either the wt or mutant hTERT
promoter (Figs. 7A and B). The E7m protein also could not
augment E6 induction of wt hTERT promoter (Fig. 7A).
Consistent with these changes in hTERT promoter activity,
quantitative TRAP assays revealed that E7m could not inde-
pendently induce telomerase or augment E6-induction of telo-
merase in stable cell strains (Fig. 7C). Six cell strains were
generated from primary keratinocytes via double retroviral
transductions (pLXSN and pBABE, pLXSN-16E6 and pBABE,
pLXSN and pBABE-16E7, pLXSN-16E6 and pBABE-16E7,
pLXSN and pBABE-16E7, pLXSN-16E6 and pBABE-
16E7m). All of the cells expressed the appropriate E6, E7 or
E7m genes and the corresponding expression of p53 and pRb
proteins was verified by Western blotting (data not shown). The
quantitative TRAP data showed that the telomerase activity of
these cells paralleled those that were generated with single
transduction (Fig. 7C). However, these double transduction
experiments allowed us to conclude that pRb-binding was
essential for E7 to induce telomerase activity in cells.
Discussion
We have previously shown that the E6 oncoprotein of HPV-
16 induces hTERT transcription in primary HFK cells through
Myc binding sites (Gewin and Galloway, 2001; McMurray and
McCance, 2003; Oh et al., 2001; Veldman et al., 2001).
However, E6 does not induce Myc expression (Gewin and
Galloway, 2001; Oh et al., 2001; Veldman et al., 2001) or Myc
binding to the hTERT promoter (Galloway et al., 2005; Liu et al.,
2005; Sekaric et al., 2008; Veldman et al., 2003). Although the
exact mechanisms by which E6 induces hTERT transcription
still remains unknown, E6 associates with Myc in vitro and in
vivo and both E6 and Myc bind to the core promoter. More
importantly, E6AP is required for the transactivation of hTERT
by E6 (Galloway et al., 2005; Gewin et al., 2004; James et al.,
2006; Kelley et al., 2005; Liu et al., 2005) and for E6 association
with the promoter (Liu et al., 2005). In contrast to the above
studies, a single recent report suggests that E6AP is not required
for hTERT promoter induction (Sekaric et al., 2008). The
etiology of these experimental differences is currently unclear
but may derive from the characteristics of the E6 mutants
employed. Clearly the specific knockdown of E6AP interferes
with promoter induction.
Fig. 8. A working model for regulation of the hTERT promoter by E6 and E7.
Results from the current and previous studies are summarized to illustrate the
possible mechanism for regulation of the hTERT promoter by the HPV E6 and
E7 oncoproteins. A critical regulator of hTERT transcription is the binding of
Myc/Max to the promoter E box, as well as the physical interaction of E6/E6AP
with this E box site. In addition, the interaction of E7 with the pRb/E2F site is
also involved in regulating promoter activity. The transcription start site for
hTERT mRNA is indicated.
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regulatory proteins present on the hTERT promoter. Ubiquitina-
tion (with or without subsequent protein degradation) plays
a critical role in the control of transcription factor activity
(Conaway et al., 2002; Muratani and Tansey, 2003), and we
postulate that proteins at or nearby the proximal E box are
potential targets. For example, Galloway et al. have shown the
NFX1-91 contributes to the repression of hTERT in primary
cells and is ubiquitinated by E6/E6AP (Galloway et al., 2005;
Gewin et al., 2004). In addition, the BRCA1 tumor suppressor
protein has been shown to bind at the hTERT E box and to
suppress expression (Xiong et al., 2003), and E6 is capable of
binding BRCA1 and relieving this repression (Zhang et al.,
2005). It is possible that this relief of suppression is mediated by
the ubiquitination/degradation of BRCA1. Myc is another
potential target for ubiquitination and degradation by E6AP.
Indeed, the stability and transcriptional activity of Myc is
already known to be regulated by ubiquitination via the Skp2
and/or Fbw7 ubiquitin ligases (Amati, 2004; Kim et al., 2003;
von der Lehr et al., 2003;Welcker et al., 2004; Yada et al., 2004).
In this study, we observed a significant decrease in telo-
merase activity in E6/E7 transduced HFKs or tumor cells after
the cells were treated with Myc-specific siRNA (Figs. 3A and
B, and 4A), suggesting an important role for Myc in
maintaining telomerase activity in HPV-positive cells. How-
ever, ChIP experiments by us and others have demonstrated that
Myc binds to the hTERT promoter in the absence or presence of
E6 (Galloway et al., 2005; Liu et al., 2005; Sekaric et al., 2008;
Veldman et al., 2003), suggesting that unlike overexpression of
exogenous Myc (Liu et al., 2007), endogenous Myc is
insufficient to activate telomerase. Potentially Myc could be
modified by E6 or E6/E6AP, thereby altering local chromatin
structure and permitting active gene transcription. E6 or E6/
E6AP-dependent changes in the acetylation of histones at the
hTERT promoter (Galloway et al., 2005; James et al., 2006)
(our unpublished data) have been observed. Interesting, E6
appears to function in both p53-dependent and -independent
pathways and can either positively (in the case of the hTERT
promoter) or negatively (p21 promoter) regulate promoter
activity (Liu et al., 2005; Sekaric et al., 2008; Thomas and
Chiang, 2005; Veldman et al., 2003).
As mentioned previously, the hTERT promoter has no TATA
box and is relatively weak. The core promoter contains many
known transcription factor binding sites, including those for Myc
(E boxes), E2F, Sp1, Ets-1, CBF1, NF-kB sites. The Myc (USF
also binds to same site) and Sp1 binding sites contribute to
promoter transactivation by E6 (Galloway et al., 2005; Gewin and
Galloway, 2001; McMurray andMcCance, 2003; Oh et al., 2001;
Veldman et al., 2001, 2003). In addition to these known activators,
we have shown in the current study that E7, pRb pocket proteins
and the E2F binding site regulate the hTERT promoter. These
findings were dependent upon the development of a more precise,
quantitative technique for measuring hTERT mRNA and telo-
merase activity (Fig. 5A, B). During the course of this study, other
laboratories have shown that the pRb/E2F pathway is involved
in the regulation of telomerase in gliomas and human fibroblasts
(Alonso et al., 2005, 2006; Won et al., 2004).In brief, our studies demonstrate that E7 alone induces the wt
hTERT two-fold, and augments E6-induced hTERT promoter
activity (Figs. 6B and 7A). Mutation of the E2F site in the
hTERT promoter abrogated the ability of E7 to induce the
hTERT promoter or to enhance the ability of E6 to induce the
promoter (Figs. 6B and 7B). The basal activity of the hTERT
promoter was also increased by mutation of the E2F site
(Fig. 6B). These data indicate that the E2F site in the hTERT
promoter functions as an inhibitory element in normal
keratinocytes, and responds to changes in pRb/E2F pathway.
Indeed, recent data from other laboratories demonstrate that pRb
and E2F proteins associate with the hTERT promoter and
regulate the activity in glioma cells and fibroblasts. Our studies
have also shown that the ability of E7 to bind pRb is essential for
E7 promoter enhancement (Fig. 7A, B), as well as an
augmentation of the telomerase activity in cells (Fig. 7C).
However, E7 alone is insufficient to initiate the transcription of
the endogenous hTERT in primary keratinocytes (Fig. 5A, C),
suggesting that the pRb/E2F pathway is not the primary reason
for repression of the hTERT promoter in keratinocytes.
Telomerase activity is one of the major hallmarks of
malignancy and many cellular factors contribute to the activation
and maintenance of this activity. While it is clear that the E6
gene of the high-risk HPVs induces hTERT transcription during
cell immortalization, it also appears that the E6 gene is required
to maintain this expression even in cancer cells. Our current
results indicate that the HPV E7 oncogene also contributes to
the induction and maintenance of telomerase activity and that
the pRb pathway is critical for regulating this effect (Fig. 8).
Materials and methods
Plasmids
Expression plasmids (pJS55E6, pJS55E7) coding E6 and E7
of HPV-16 in a modified pSG5 vector (Strategene) for transient
transfection in this study, retrovirus vectors expressing E6, E7,
or E6/E7 (pLSXN-E6, pLXSN-E7, pLXSN-E6/E7) for stable
620 X. Liu et al. / Virology 375 (2008) 611–623cell lines, and hTERT promoter reporter plasmid (pGL3B-
hTERT core promoter, defined as pGL3B-255 previously) were
described previously (Sherman and Schlegel, 1996; Veldman
et al., 2001, 2003). The hTERT expression vector (pCI-hTERT)
was a gift from Dr. Robert Weinberg (MIT). The E7 mutant
defective for pRb binding in pCMV was a gift from Dr. Karl
Munger (Harvard University), we performed PCR to amplify
this E7 mutant using the following primers 5′-ATCGAATT-
CATGCATGGAGATACACCTAC-3′ with EcoR I site at 5′end
and 5′-TAGCTCGAGTTATGGTTTCTGAGAACAGA-3′
with Xho I site at its 5′ end, the double digestion products
with EcoR I and Xho I were ligated with the EcoR I and Xho I
fragment of pJS55, resulting a new construct, pJS55-16E7m,
defective for pRb binding. To generate wt 16 E7 and its pRb
binding defective E7 mutant in pBABE-puro (pBABE-16E7
and pBABE-16E7m), PCR products from the following primers
5′-ATCGGATCCATGCATGGAGATACACCTAC-3′ with
BamH I site at its 5′ end and 5′-TACGAATTCTTATGGT-
TTCTGAGAACAGA-3′ with EcoR I site at its 5′ end were
digested with BamH I and EcoR I, and then ligated with the
BamH I and EcoR I fragment of pBABE-puro vector. To obtain
a pGL3B-hTERT promoter with mutated E2F site (pGL3B-
hTERT E2Fm, CGGCGCGAGTTT–CGGAACGATTT), over-
lapping PCR was using to build in a mutated E2F site in
pGL3B-hTERT core promoter (Veldman et al., 2001, 2003).
Briefly, using pGL3B-hTERT as a DNA template, the first
round PCR was done with primer sets oXL006 5′-AGTACCG-
GAATGCCAAGCTTAC-3′ and oXL067 5′-CTCTCCTC-
GCGGAACGAGTTTCAGGCAGCGCTGCG-3′, and oXL022
5′-CTTGGAGCGGCCGCAATAAAATATC-3′ and oXL068 5′-
CTGCCTGAAACTCGTTCCGCGAGGAGAGGGCGGG-3′,
respectively; the second PCR was done with primers oXL006
and oXL022 using mixture of the 1st round PCR products as
template, the double digestion of the 2nd PCR product with Hind
III and Xho I was ligated with the Hind III and Xho I fragment of
pGL3-basic vector. The expected mutation for E2F binding site
was confirmed by sequencing.
Retroviruses
Retrovirus packaging cells, SD3443, were transfected with
pLXSN, pBABE-puro vectors with either E6 or E7, or both E6
and E7 as described above using LipofectAmine 2000 (Invitro-
gen) as suggested by the manufacturer. Culture supernatants
containing retrovirus were collected 24 h after transfections.
Cell culture and stable lines selection
Primary human foreskin keratinocytes (HFKs) were cultured
from neonatal foreskins as described (Schlegel et al., 1988) and
maintained in keratinocyte growth media (Gibco-BRL), supple-
mented with gentamycin (50 μg/ml). Primary HFKs P2 were
infected with amphotropic LXSN or pBABE-puro retroviruses
expressing HPV-16E6, E7, E7 m or both E6 and E7 (or E7 m)
described above. Retrovirus-infected cells were selected in G418
(100 μg/ml) or puromycin (200 ng/ml) for 5 days. Resistant
colonies were pooled and passaged every 3–4 days (1 to 4 ratio).SiHa (HPV16 positive cervical cancer cell line), C33A (HPV
negative cervical cancer cell line) cells were maintained in
complete DMEMmedium. All cells were cultured on non-coated,
plastic tissue culture dishes or flasks.
Reverse transcription and polymerase chain reaction
(RT-PCR)
Total cellular RNA was isolated with TRIZol reagent
(Invitrogen) and treated with DNA-free kit (Ambion) according
to the manufacturer's instructions. First-strand cDNA was
synthesized with some modifications using 2 μg of total cellular
RNA following the instructions of Superscript First-Strand
Synthesis System for RT-PCR (Invitrogen). Five percent of the
RNase H-treated cDNA products were subjected to PCR
amplification in a total volume of 50 μl containing 10 μmol/L
sense primer and 10 μmol/L anti-sense primer as described in the
manufacturer's protocol. Initial denaturation for 3 min at 94 °C
was followed by 30 cycles of PCR amplification (94 °C for 30 s,
52 °C for 30 s, 72 °C for 60 s). PCR products were analyzed for
E6, E7, hTERC, hTERT, andGAPDHmRNAwith 1.5% agaraose
gel. The primers used for RT-PCR were: 5′-CAACAAACCG-
TTGTGTGAT-3′ and 5′-CGTGTTCTTGATGATCTGC-3′ for
unspliced E6; 5′-ATGCATGGAGATACACCTAC-3′ and 5′-CA-
TTAACAGGTCTTCCAAAG-3′ for E7; 5′-GGCTCTTTTTC-
TACCGGAAG-3′ and 5′-ACAAAGTACAGCTCAGGCGG-3′
for hTERT mRNA; 5′-TCTAACCCTAACTGAGAAGGGCG-
TAG-3′ and 5′-GTTTGCTCTAGAATGAACGGTGGAAG-3′
for hTERC; and 5′-CTCAGACACCATGGGGAAGGTGA-3′
and 5′-ATGATCTTGAGGCTGTTGTCATA-3′ for GAPDH
mRNA.
Real-time quantitative RT-PCR (QRT-PCR)
Taqman real-time QRT-PCR was performed on the Bio-Rad
iCyclerMyiQ for quantitation of hTERTmRNAusing primers and
probes (sense primer, 5′-TGACACCTCACCTCACCCAC-3′,
anti-sense primer, 5-CACTGTCTTCCGCAAGTTCAC-3′, and
Tagman probe, 5′-ACCCTGGTCCGAGGTGTCCCTGAG-3′)
as previously reported (Fu et al., 2003). All samples were run in
triplicate and each reaction contained the cDNA from 50 ng of
RNA. Standard curves were created for each run using 10-fold
serial dilutions of pCI-hTERT cDNA expression vector. The
concentration of each mRNAwas expressed as fg of the respective
cDNA vector.
Western blot
Stable cell lines in 10-mm dishes or cells with siRNA duplex
treatment in 6-well plate werewashed once with PBS, lysed in 2×
SDS gel electrophoresis sample buffer. Proteins were separated
on a 4 to 20% Tris–glycine gradient gel (Invitrogen) and then
were electrophoretically transferred to an Immobilon-P poly-
vinylidane difluorid (PVDF) membrane (Millipore). The mem-
branes were blocked in 5% milk-PBST or 5% BSA-PBST
and incubated with the primary antibodies, mouse anti-p53
monoclonal antibody (Santa Cruz, mouse monoclonal, 1:1000
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or β-actin (Sigma, mouse monoclonal, 1:10000 dilution). The
secondary antibodies, HRP-conjugated goat anti-mouse IgG and
anti-rabbit IgG antibodies (Santa Cruz), were used at a dilution of
1:10,000. The membranes were visualized by using Western
Blotting Chemiluminescence Luminol Reagent (Santa Cruz).
siRNA transfection
The siRNA target sequences were as follows (Kelley et al.,
2005): for 16E6 siRNA duplex target (nt385–403), 5′-ACC-
GTTGTGTGATTTGTTA-3′; for 18E6 siRNA duplex target
(nt231–249), 5′-GAGGTATTTGAATTTGCAT-3′; for 16E7
siRNA duplex target (nt741–767), 5′-GTGTGACTCTACGC-
TTCGGTTGTGCGT-3′; for c-myc siRNA duplexes targeting
four different region in myc (Smartpool from Dharmacon), the
targets are nt437–455 5′-CAGAGAAGCTGGCCTCCTA-3′,
nt360–378 5′-CGACGAGACCTTCATCAAA-3, nt1263–1281
5′-GAAACGACGAGAACAGTTG-3′ and nt908–926 5′-CCA-
CACATCAGCACAACTA-3′. 60–70% confluency of C33A
cells or 70–80% confluency of SiHa cells, pLXSN-16E6/E7 or
pLXSN-16E6/pBABE-16E7 transduced HFKs were tranfected
with a final concentration of 40 nMof negative control siRNA, E6-
specific siRNA (Dharmacon), or E7-specific siRNA (IDT), or
Myc specific siRNA duplex mixture (Dharmacon, Smartpool)
with LipofectAmine 2000 (Invitrogen) following the manufac-
turer's instructions. Cells were harvested for Luciferase assay 24 h
posttransfection, and for RT-PCR, western blot, and TRAP assay
48 h posttransfection, respectively. For Luciferase assay, SiHa,
C33A, pLXSN-16E6/E7, and pLXSN-16E6/pBABE-16E7 trans-
duced HFK cells were co-tranfected with siRNA duplexes plus
pGL3B-hTERT and Renilla reniformis luciferase gene as
described below.
Luciferase assay
1×105 telomerase-negative HFKs, pLXSN-16E6/E7 trans-
duced HFKs, pLXSN16E6/pBABE-16E7 transduced HFKs,
SiHa, or C33Acells were seeded onto 24-well plates and grown
overnight. Transient transfections were performed using
LipofectAmine 2000 reagent (Invitrogen) according to the
protocol provided by the manufacturer. Cotransfections were
performed using 0.5 µg of a core hTERT reporter plasmid
(pGL3B-hTERTor its mutant pGL3B-hTERT E2Fm) and 20 ng
of each expression vector as indicated (pJS55-16E6, pJS55-
16E7 or both) or empty vectors as control for basal promoter
activity. Cells also were cotransfected with 2 ng of the pRL-
CMV plasmid (Promega), which contains the Renilla reniformis
luciferase gene as a transfection control. Firefly and Renilla
luciferase activities were measured 24 h after transfection using
the Dual luciferase reporter assay system (Promega).
Telomeric repeat amplification protocol (TRAP) and real-time
quantitative TRAP (Q-TRAP)
Human keratinocytes were grown in 100-mm tissue-culture
dishes to 80% confluence, harvested by trypsinization, washed incold PBS, and transferred to a microfuge tube. Cell pellets were
lysed for 30min on ice in 400 μl of telomeric repeat amplification
protocol (TRAP) buffer (0.5% Chaps, 10 mmol/L Tris, pH 7.5,
1 mmol/L MgCl2, 1 mmol/L EGTA, 5 mmol/L β-ME, 10%
glycerol, 0.1mmol/L 4-(2-amino-ethyl)benzene-sulfonyl fluoride
hydrochloride (AEBSF). Lysates were centrifuged at 14,000 ×g
for 5 min at 4 °C, the supernatant was transferred to a new tube,
and protein concentration was determined (Bio-Rad, Richmond,
CA). ATRAP assay was performed on 1 μg of protein lysates as
described (Baege et al., 2002; Veldman et al., 2001). Twenty
percent of the PCR products were separated on 10% nondenatur-
ing polyacrylamide gels and visualized using the Gelcode color
silver-staining kit (Pierce, Rockford, IL).
Quantitative TRAP assay was performed as described before
(Fu et al., 2003) with SYBR Green Supermixure (Bio-Rad). A
standard curve was produced for the real-time Q-TRAP assay
using serially diluted 293 cell extracts. All samples were run in
triplicate. This assay is linear over at least a 500-fold range
(0.008 to 4 μg of 293 cell protein input).
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